Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study

AIDS

Volumn 13, Issue 18, 1999, Pages 2547-2554

  Junghans, Cornelia ^a   Low, Nicola ^a   Chan, Philip ^a   Witchi, Anne ^c   Vernazza, Pietro ^b   Egger, Matthias ^a,c  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^c Canynge Hall ^*

Author keywords

Antiretroviral therapy; Cohort study; Combination therapy; Drug users; Education; Health service accessibility; Healthcare economics; Homosexual men; Natural history; Opportunistic infections; Protease inhibitors; Switzerland; Viral load; Women

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DELAVIRDINE; EFAVIRENZ; INDINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; COHORT ANALYSIS; DISEASE COURSE; EDUCATION; FEMALE; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGRESSION ANALYSIS; SWITZERLAND; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; EDUCATION; FEMALE; HIV-1; HUMANS; MALE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SEX FACTORS; SURVIVAL ANALYSIS; SWITZERLAND; TIME FACTORS;

EID: 0033402880     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199912240-00008     Document Type: Article

References (37)

1. 1. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. URL: US Health and Human Services; 1999. http://www.hivatis.org/trtgdlns.html.
2. 2. Gazzard B, Moyle G. 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Writing Committee. Lancet 1998, 352:314-316.
3. 3. Egger M, Hirschel B, Francioli P et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 1997, 315:1194-1199.
4. 4. Palella FJJ, Delaney KM, Moorman AC et el. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
5. 5. European Secondary Prevention Study Group. Translation of clinical trials into practice: a European population-based study of the use of thrombolysis for acute myocardial infarction. Lancet 1996, 347:1203-1207.
6. 6. Moore RD, Stanton D, Gopalan R, Chaisson RE. Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med 1994, 330:763-768.
7. 7. Crystal S, Sambamoorthi U, Merzel C. The diffusion of innovation in AIDS treatment: zidovudine use in two New Jersey cohorts. Health Services Res 1995, 30:593-614.
8. 8. Bassetti S, Battegay M, Furrer H et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. J Acquired Immune Defic Syndr Hum Retrovirol 1999, 21:114-119.
9. 9. Powderly WG, Landay A, Lederman MM. Recovery of the immune system with antiretroviral therapy: The end of opportunism? JAMA 1998, 280:72-77.
10. 10. Furrer H, Egger M, Opravil M et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med 1999, 340:1301-1306.
11. 11. Ho DD. Time to hit HIV, early and hard. N Engl J Med 1995, 333:450-451.
12. 12. Walker BD, Basgoz N. Treat HIV-1 infection like other infections - treat it. JAMA 1998, 280:91-93.
13. 13. Li TS, Tubiana R, Katlama C, Calvez V, Ait MH, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998, 351:1682-1686.
14. 14. Ledergerber B, von Overbeck J, Egger M, Lüthy R. The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics. Soz Praventivmed 1994, 39:387-394.
15. 15. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41:1-19.
16. 16. Hermans P, Lundgren J, Sommereijns B et al. Epidemiology of AIDS-related Kaposi's sarcoma in Europe over 10 years. AIDS in Europe Study Group. AIDS 1996, 10:911-917.
17. 17. Vella S, Giuliano M, Floridia M et al. Effect of sex, age and transmission category on the progression to AIDS and survival of zidovudine-treated symptomatic patients. AIDS 1995, 9:51-56.
18. 18. Gebhardt M. Praevalenz von HIV und AIDS in der Schweiz (Ende 1997). In: AIDS und HIV in der Schweiz. Epidemiologische Situation Ende 1997. Bern: Bundesamt fuer Gesundheit; 1998.
19. 19. Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O, Moore RD. Self-reported antiretroviral therapy in injection drug users. JAMA 1998, 280:544-546.
20. 20. Strathdee SA, Palepu A, Cornelisse PG et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998, 280:547-549.
21. 21. Feinberg M. Hidden dangers of incompletely suppressive antiretroviral therapy. Lancet 1997, 349:1408-1409.
22. 22. Paterson D, Swindells S, Mohr J et al. How much adherence is enough. A prospective study of adherence to protease inhibitor therapy using MEMSCaps. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, Il, 31 January-4 February 1999 [Abstract 92].
23. 23. Kaplan A, Golin C, Beck K et al. Adherence to protease inhibitor therapy and viral load. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, Il, 31 January-4 February 1999 [Abstract 96].
24. 24. von Overbeck J, Egger M, Smith GD et al. Survival in HIV infection: do sex and category of transmission matter? AIDS 1994, 8:1307-1313.
25. 25. Egger M, Twisselmann W, Ledergerber B. Differences in progression of HIV infection between men and women [letter]. BMJ 1995, 310:941.
26. 26. Bratt G, Karlsson A, Leandersson A-C, Albert J, Wahren B, Sandstrom E. Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment. AIDS 1998, 12:2193-2202.
27. 27. Chaisson RE, Keruly JG, Moore RD. Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med 1995, 333:751-756.
28. 28. Moore RD, Hidalgo J, Sugland BW, Chaisson RE. Zidovudine and the natural history of the acquired immunodeficiency syndrome. N Engl J Med 1991, 324:1412-1416.
29. 29. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom free HIV infection. Lancet 1994, 343:871-881.
30. 30. Brun VF, Boucher C, Loveday C et al. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee, Lancet 1997, 350:983-990.
31. 31. Katzenstein D. Combination therapies for HIV infection and genomic drug resistance. Lancet 1997, 330:970-971.
32. 32. Burman WJ, Reves RR, Cohn DL. The case for conservative management of early HIV disease. JAMA 1998, 280:93-95.
33. 33. Buckingham W, Gebbie KM. Treatment policy: gold standard or golden calf? The AIDS Reader 1998, 8:160-215.
34. 34. Ledergerber B, Egger M, Opravil M et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999, 353:863-868.
35. 35. Gail MH. Use of observational data, including surveillance studies, for evaluating AIDS therapies. Stat Med 1996, 15:2273-2288.
36. 36. Delta Coordinating Committee and Virology Group. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. AIDS 1999, 13:565-573.
37. 37. Phillips AN, Smith GD, Johnson MA. Will we ever know when to treat HIV infection? BMJ 1996, 313:608-610.